Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Business Wire
- Veligrotug, with recent positive phase 3 topline data in both active and chronic thyroid eye disease (TED), has the potential to transform the standard of care in TED with a differentiated clinical profile achieved with less drug and fewer infusions; Biologics License Application (BLA) submission on track for second half of 2025 -- REVEAL-1 and REVEAL-2, phase 3 clinical trials for subcutaneous (SC) VRDN-003 in active and chronic TED respectively, are currently dosing patients; topline data for both trials, which are evaluating VRDN-003 dosed Q4W or Q8W, is on track for the first half of 2026 -- Investigational New Drug (IND) submitted in December 2024 for VRDN-006, an Fc fragment inhibitor of the neonatal Fc receptor (FcRn); proof-of-concept IgG reduction clinical data in healthy volunteers anticipated in the third quarter of 2025 -- VRDN-008, a bispecific FcRn inhibitor with an extended half-life, progressing with preclinical studies as planned; additional preclinical data expecte
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye DiseaseBusiness Wire
- Viridian Therapeutics (NASDAQ:VRDN) had its price target raised by analysts at Wedbush from $42.00 to $47.00. They now have an "outperform" rating on the stock.MarketBeat
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Viridian Therapeutics (NASDAQ:VRDN) was given a new $47.00 price target on by analysts at William Blair.MarketBeat
VRDN
Earnings
- 2/27/25 - Beat
VRDN
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/5/25 - Form 10-Q
- 11/5/25 - Form 8-K
- VRDN's page on the SEC website